Eli Lilly has chalked up another regulatory approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest pharma market. The National Medical ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

GlobalData analysts are predicting an Alzheimer’s disease market boom, tipping its value across major regions to increase ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Eisai is seeking approval for an injectable version of Leqembi while Eli Lilly is developing a new injectable drug. These ...

Lilly anticipates revenue growth contributions in 2025 from new Lilly medicines such as Jaypirca, Ebglyss, Omvoh and Kisunla; approvals of new indications ... Hot Stocks on TipRanks >> Read More on ...

Eli Lilly and Company (NYSE: LLY) today announced that the National Medical Products Administration (NMPA) in China has approved Kisunla™ (donanemab-azbt, 350 mg/20 mL every four weeks injection ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Is Eli Lilly a good stock to buy on the dip? On Jan. 14, CEO David Ricks told investors that 2024 sales would come in at ...

Is Eli Lilly a good stock to buy on the dip ... Last July, Lilly's Alzheimer's disease candidate Kisunla earned approval from the FDA to treat Alzheimer's disease. Intended for early-stage ...